Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Sees Large Growth in Short Interest

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the recipient of a significant growth in short interest in January. As of January 30th, there was short interest totaling 429 shares, a growth of 62.5% from the January 15th total of 264 shares. Based on an average daily volume of 50,048 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the shares of the stock are sold short. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 50,048 shares, the days-to-cover ratio is currently 0.0 days.

Matinas Biopharma Stock Performance

MTNB traded down $0.02 during trading on Friday, reaching $0.59. 28,401 shares of the company traded hands, compared to its average volume of 40,484. The company has a market cap of $3.78 million, a P/E ratio of -0.17 and a beta of 1.31. Matinas Biopharma has a 12-month low of $0.47 and a 12-month high of $3.09. The firm has a fifty day simple moving average of $0.67 and a 200 day simple moving average of $1.21.

Matinas Biopharma (NYSEAMERICAN:MTNB) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Matinas Biopharma

An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC acquired a new position in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned 0.72% of Matinas Biopharma as of its most recent SEC filing. Institutional investors and hedge funds own 11.77% of the company’s stock.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.